SIRT1 inhibitors and stem cell rejuvenation
Provided herein are, inter alia, methods and compositions for treating or preventing diseases using SIRT1 inhibitors. The methods provided herein are particularly useful for treating or preventing age-related hematological diseases as well as cancerous hematological diseases. Further provided herein are hematopoietic cells useful for treating or preventing hematological diseases.
1. A method of treating or preventing a hematological disease in a subject in need thereof, said method comprising administering a therapeutically effective amount of a SIRT1 inhibitor to a subject, thereby treating or preventing a hematological disease in said subject, wherein said disease is not a cancerous hematological disease, said hematological disease is an age-related hematological disease in an elderly subject and said SIRT1 inhibitor is a naphthol inhibitor, an indole inhibitor, a nicotinamide inhibitor, inauhzin or an antisense nucleic acid.
2. The method of claim 1 , wherein said hematological disease is a red blood cell disease, a lymphoid disease or a myeloid disease.
3. The method of claim 2 , wherein said red blood cell disease is anemia.
4. A method of increasing immune competence in a subject in need thereof, said method comprising administering a therapeutically effective amount of a SIRT1 inhibitor to a subject, thereby increasing immune competence in said subject, wherein said subject is an elderly subject and said SIRT1 inhibitor is a naphthol inhibitor, an indole inhibitor, a nicotinamide inhibitor, inauhzin or an antisense nucleic acid.
5. A method of treating or preventing a hematological disease in a subject in need thereof said method comprising:
(i) isolating a hematopoietic stem cell (HSC) from a subject, thereby forming an isolated HSC;
(ii) contacting said isolated HSC with a SIRT1 inhibitor, thereby forming a rejuvinated HSC;
(iii) administering said rejuvinated HSC to said subject, thereby treating or preventing a hematological disease in said subject.
6. The method of claim 5 , wherein said the hematological disease is a cancerous hematological disease or a non-cancerous hematological disease.
7. The method of claim 5 , wherein said rejuvinated HSC is allowed to divide prior to said administering of step (iii).
8. The method of claim 5 , wherein said hematological disease is an age-related hematological disease.
9. The method of claim 5 , wherein said hematological disease is a red blood cell disease, a lymphoid disease or a myeloid disease.
10. The method of claim 5 , wherein said SIRT1 inhibitor is a naphthol inhibitor, an indole inhibitor, a nicotinamide inhibitor, an urea inhibitor, a polyphenol inhibitor, a thienopyrimidine carboxamide inhibitor, inauhzin, a peptide inhibitor or an antisense nucleic acid.
11. A method of forming a red blood cell, said method comprising:
(i) contacting a hematopoietic stem cell (HSC) with a SIRT1 inhibitor, thereby forming a rejuvenated HSC; and
(ii) allowing said rejuvenated HSC to divide, thereby forming a red blood cell, wherein said contacting occurs in an elderly subject and said SIRT1 inhibitor is a naphthol inhibitor, an indole inhibitor, a nicotinamide inhibitor, inauhzin or an antisense nucleic acid.